P/E ratio for Coherus BioSciences (CHRS)
P/E ratio as of April 2024 (TTM): -0.6566
According to Coherus BioSciences 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.656627. At the end of 2022 the company had a P/E ratio of -2.11.
P/E ratio history for Coherus BioSciences from 2014 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -2.11 | -49.06% |
| 2021 | -4.13 | -144.01% |
| 2020 | 9.39 | -33.21% |
| 2019 | 14.1 | -598.93% |
| 2018 | -2.82 | 45.77% |
| 2017 | -1.93 | -78.22% |
| 2016 | -8.88 | 131.67% |
| 2015 | -3.83 | 5.4% |
| 2014 | -3.64 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Amgen AMGN | 19.3 | -3,044.05% | 🇺🇸 USA |
 Repligen
RGEN | 82.0 | -12,580.78% | 🇺🇸 USA |
 Acorda Therapeutics
ACOR | -0.0676 | -89.70% | 🇺🇸 USA |
 Arena Pharmaceuticals
ARNA | N/A | N/A | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.